DCT and melanoma: Using inhibitors to reduce NAT10 expression in melanocytes can inhibit the expression of melanin‐stimulating genes (such as the genes encoding dopa oxidase (DCT) and tyrosinase in B16F10 melanoma cells), leading to reduced melanin synthesis and increased S‐phase cell cycle arrest, thereby inhibiting the growth and proliferation of malignant melanoma cells in vitro and in vivo.117